Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Theodore Sunki Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8481-6581; OpenAlex author ID A5044225007, A5124884177, A5135364652; NIH RePORTER profile ID 8636914. Sources: ClinicalTrials.gov.

Their work

Papers
75 (first author 5, last author 14)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
255
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: 3 papers · 2013: 4 papers · 2014: 5 papers · 2015: 1 paper · 2016: 3 papers · 2017: 5 papers · 2018: 6 papers · 2019: 7 papers · 2020: 5 papers, 1 trial · 2021: 8 papers · 2022: 8 papers · 2023: 7 papers · 2024: 4 papers · 2025: 3 papers · 2026: 4 papers, 1 grant

Papers 50 of 75

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  4. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  5. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  6. The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer Co-author DOI 10.1101/2025.08.26.672505↗
  7. Evaluating CBCT-Guided Adaptive Radiotherapy for Pancreatic Cancer Using Synthetic CBCT Data. Co-author DOI 10.3390/curroncol32020060↗
  8. A Multi-Institutional Safety and Feasibility Study Exploring the Use of Hydrogel to Create Spatial Separation between the Pancreas and Duodenum in Patients wit… First author DOI 10.1016/j.prro.2023.11.011↗
  9. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
  10. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  11. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  12. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  13. Neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.1038/s41571-023-00746-1↗
  14. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  15. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  16. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-22-1630↗
  17. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-022-12976-1↗
  18. MRI-Based Tumor Necrosis Depiction in Pancreatic Ductal Adenocarcinoma: Can It Predict Tumor Aggressiveness? Co-author DOI 10.3390/cancers15082313↗
  19. Measuring the Effect of Local Control From Radiotherapy in Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1001/jamaoncol.2021.7037↗
  20. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  21. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  22. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  23. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  24. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-21-4165↗
  25. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  26. Treatment-associated remodeling of the pancreatic cancer endothelium at single-cell resolution. Co-author DOI 10.3389/fonc.2022.929950↗
  27. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Co-author DOI 10.1007/s11307-020-01569-7↗
  28. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  29. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  30. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Last author DOI 10.1038/s43018-021-00269-7↗
  31. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  32. Liver Metastasis-Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients: Data From a Multi-institu… Co-author DOI 10.1097/mpa.0000000000001822↗
  33. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  34. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Co-author DOI 10.1245/s10434-020-09444-z↗
  35. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  36. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001590↗
  37. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  38. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  39. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoad… Co-author DOI 10.1245/s10434-019-08084-2↗
  40. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Last author DOI 10.1001/jamaoncol.2019.0892↗
  41. Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geomet… Last author DOI 10.1002/acm2.12528↗
  42. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-018-0196-2↗
  43. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  44. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  45. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.19.00946↗
  46. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Co-author DOI 10.1634/theoncologist.2018-0114↗
  47. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Last author DOI 10.1001/jamaoncol.2018.0329↗
  48. Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. Last author DOI 10.1016/j.prro.2017.09.008↗
  49. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Last author DOI 10.1097/coc.0000000000000336↗
  50. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Last author DOI 10.1097/coc.0000000000000349↗

Trials 2

  1. Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer Principal investigator NCT04361162↗
  2. Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer Principal investigator NCT00438256↗

Grants 1

  1. High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers P01CA295486↗

Closest collaborators

The 25 strongest of 255 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer Yon-Li Wo · 46 shared papers, 2012–2026 · strength 5.05
  2. David P. Ryan · 39 shared papers, 2011–2026 · strength 3.56
  3. Keith D. Lillemoe · 32 shared papers, 2013–2026 · strength 3.26
  4. Motaz Qadan · 22 shared papers, 2019–2026 · strength 3.07
  5. Cristina Rosa Ferrone · 34 shared papers, 2013–2024 · strength 3.07
  6. David Tsai Ting · 16 shared papers, 1 shared grant, 2015–2026 · strength 2.56
  7. Lawrence Scott Blaszkowsky · 26 shared papers, 2011–2026 · strength 2.45
  8. Carlos F. Fernandez-del Castillo · 29 shared papers, 2011–2024 · strength 2.36
  9. Colin D. Weekes · 17 shared papers, 2019–2026 · strength 2.23
  10. Carlos Fernández-del Castillo · 15 shared papers, 2013–2026 · strength 1.74
  11. Aparna R. Parikh · 12 shared papers, 2018–2026 · strength 1.49
  12. William L. Hwang · 4 shared papers, 1 shared grant, 2020–2026 · strength 1.41
  13. Hannah Johnson Roberts · 7 shared papers, 2024–2026 · strength 1.27
  14. Vikram Deshpande · 12 shared papers, 2013–2022 · strength 0.92
  15. Samuel Jacob Klempner · 1 shared grant, 2026 · strength 0.86
  16. Andrew Louis Warshaw · 10 shared papers, 2013–2023 · strength 0.83
  17. Mari A. Mino-Kenudson · 7 shared papers, 2011–2025 · strength 0.73
  18. Ryan David Nipp · 8 shared papers, 2017–2022 · strength 0.64
  19. Theodoros P. Michelakos · 7 shared papers, 2017–2022 · strength 0.63
  20. Amol Kumar Narang · 3 shared papers, 2024–2026 · strength 0.62
  21. Onofrio A. Catalano · 5 shared papers, 2021–2024 · strength 0.61
  22. Eunice Lee Kwak · 14 shared papers, 2011–2019 · strength 0.61
  23. Zhi Ven Fong · 4 shared papers, 2018–2024 · strength 0.57
  24. Jimmy A. Guo · 4 shared papers, 2020–2025 · strength 0.55
  25. Jon Michael Harrison · 4 shared papers, 2020–2026 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.